Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - CAD ($) |
Issued capital [member] |
Reserve of share-based payments [member] |
Warrant reserve [member] |
Retained earnings [member] |
Reserve of gains and losses from investments in equity instruments [member] |
Reserve of exchange differences on translation [member] |
Total |
|---|---|---|---|---|---|---|---|
| Balance at Dec. 31, 2024 | $ 110,742,984 | $ 7,698,304 | $ 3,776,428 | $ (117,465,829) | $ (609,420) | $ 479,316 | $ 4,621,783 |
| Balance, shares at Dec. 31, 2024 | 5,427,795 | ||||||
| IfrsStatementLineItems [Line Items] | |||||||
| Share issue costs | $ (306) | (306) | |||||
| Shares issued for the exercise of RSUs | $ 480,100 | (480,100) | |||||
| Shares issued for the exercise of RSUs, shares | 6,029 | ||||||
| Share-based payments | 288,883 | 288,883 | |||||
| Net loss | (3,424,825) | (3,424,825) | |||||
| Change in fair value of equity investments at FVOCI | 7,173 | 7,173 | |||||
| Translation of foreign operations | (16,060) | (16,060) | |||||
| Balance at Mar. 31, 2025 | $ 111,222,778 | 7,507,087 | 3,776,428 | (120,890,654) | (602,247) | 463,256 | 1,476,648 |
| Balance, shares at Mar. 31, 2025 | 5,433,824 | ||||||
| IfrsStatementLineItems [Line Items] | |||||||
| Share issue costs | $ (7,328,625) | 2,225,727 | (5,102,898) | ||||
| Shares issued for the exercise of RSUs | $ 769,023 | (769,023) | |||||
| Shares issued for the exercise of RSUs, shares | 210,709 | ||||||
| Share-based payments | 1,100,074 | 1,100,074 | |||||
| Net loss | (19,556,254) | (19,556,254) | |||||
| Change in fair value of equity investments at FVOCI | 57,113 | 57,113 | |||||
| Translation of foreign operations | (46,917) | (46,917) | |||||
| Shares issued - overallotment | $ 294,000 | 294,000 | |||||
| Shares issued - overallotment, shares | 100,000 | ||||||
| Share issue costs - overallotment | $ (28,030) | (28,030) | |||||
| Shares issued for financing | $ 56,907,745 | 56,907,745 | |||||
| Shares issued for financing, shares | 11,887,895 | ||||||
| Shares issued for the exercise of warrant | $ 67,861,616 | (2,716,408) | (4,753,719) | 60,391,489 | |||
| Shares issued for the exercise of warrants, shares | 11,712,347 | ||||||
| Warrants – equity treatment | 1,103,825 | 1,103,825 | |||||
| Balance at Dec. 31, 2025 | $ 229,698,507 | 7,347,457 | 126,534 | (140,446,908) | (545,134) | 416,339 | 96,596,795 |
| Balance, shares at Dec. 31, 2025 | 29,344,775 | ||||||
| IfrsStatementLineItems [Line Items] | |||||||
| Share issue costs | $ (5,724,416) | 2,976,521 | (2,747,895) | ||||
| Share-based payments | 244,064 | 244,064 | |||||
| Net loss | (5,628,866) | (5,628,866) | |||||
| Shares issued for financing | $ 48,033,503 | 48,033,503 | |||||
| Shares issued for financing, shares | 5,030,000 | ||||||
| Shares issued for the exercise of warrant | $ 19,367,257 | 19,367,257 | |||||
| Shares issued for the exercise of warrants, shares | 2,121,164 | ||||||
| Unrealized gain on investments available for sale | (42,857) | (42,857) | |||||
| Other comprehensive income (loss) | (39,561) | (39,561) | |||||
| Balance at Mar. 31, 2026 | $ 291,374,851 | $ 10,568,042 | $ 126,534 | $ (146,075,774) | $ (587,991) | $ 376,778 | $ 155,782,440 |
| Balance, shares at Mar. 31, 2026 | 36,495,939 |